Fusion Medical Technologies Quarterly Conference Call To Be Available on the Internet

Apr 13, 2001, 01:00 ET from Fusion Medical Technologies, Inc.

    FREMONT, Calif., April 13 /PRNewswire/ -- Fusion Medical Technologies,
 Inc. (Nasdaq:   FSON) today announced plans to release its first quarter 2001
 results on Thursday, April 19, 2001 at 7:30 a.m. (Eastern).  In conjunction
 with the release, management will host a conference call on Thursday,
 April 19, 2001, at 11:30 a.m. (Eastern).  The call will be broadcast live over
 the Internet at PR Newswire's website at (www.videonewswire.com/Fusion/041901)
     Web participants are encouraged to go to the Company's website at least
 15 minutes prior to the start of the call to register, download, and install
 any necessary audio software.  The online archive will be available
 immediately and continue through Thursday, April 26, 2001.
 
     Fusion currently markets its FloSeal(R) Matrix Hemostatic Sealant
 (FloSeal) and Proceed products in surgical procedures, other than in
 ophthalmic and urologic, as an adjunct to hemostasis when control of bleeding
 by ligature or conventional procedures is ineffective or impractical.
 FloSeal, Proceed and Fusion's products in development are based on a
 bio-resorbable and proprietary collagen-based gel.  Products in development
 are being developed for use as hemostatic sealants, as well as for other
 potential uses.  Proceed is distributed worldwide exclusively by Sulzer
 Spine-Tech.
     The United States Food and Drug Administration (FDA) granted Fusion
 approval to market FloSeal and Proceed in the United States in December 1999.
 The FDA has not cleared or approved Fusion's other products in development.
     Fusion is commercializing FloSeal and Proceed for controlling bleeding in
 a variety of settings in which conventional means of achieving hemostasis,
 such as sutures, staples, topical hemostats, or fibrin glues, are impractical
 or generally do not work effectively.  FloSeal, Proceed and Fusion's other
 products in development are based on a bio-resorbable and proprietary
 collagen-based gel.  Its products in development are being developed for use
 as hemostatic sealants, as well as for other potential uses.  Proceed is
 distributed worldwide exclusively by Sulzer Spine-Tech.
 
     Fusion Medical Technologies(TM), Fusion(TM), FloSeal(R), Proceed(TM), and
 the stylized Fusion logo are trademarks of Fusion.
 
     For further information, please contact: Lynn Johnson of Allen & Caron
 Inc, 949-474-4300, Lynn@allencaron.com, for Fusion Medical Technologies, Inc.
 
 

SOURCE Fusion Medical Technologies, Inc.
    FREMONT, Calif., April 13 /PRNewswire/ -- Fusion Medical Technologies,
 Inc. (Nasdaq:   FSON) today announced plans to release its first quarter 2001
 results on Thursday, April 19, 2001 at 7:30 a.m. (Eastern).  In conjunction
 with the release, management will host a conference call on Thursday,
 April 19, 2001, at 11:30 a.m. (Eastern).  The call will be broadcast live over
 the Internet at PR Newswire's website at (www.videonewswire.com/Fusion/041901)
     Web participants are encouraged to go to the Company's website at least
 15 minutes prior to the start of the call to register, download, and install
 any necessary audio software.  The online archive will be available
 immediately and continue through Thursday, April 26, 2001.
 
     Fusion currently markets its FloSeal(R) Matrix Hemostatic Sealant
 (FloSeal) and Proceed products in surgical procedures, other than in
 ophthalmic and urologic, as an adjunct to hemostasis when control of bleeding
 by ligature or conventional procedures is ineffective or impractical.
 FloSeal, Proceed and Fusion's products in development are based on a
 bio-resorbable and proprietary collagen-based gel.  Products in development
 are being developed for use as hemostatic sealants, as well as for other
 potential uses.  Proceed is distributed worldwide exclusively by Sulzer
 Spine-Tech.
     The United States Food and Drug Administration (FDA) granted Fusion
 approval to market FloSeal and Proceed in the United States in December 1999.
 The FDA has not cleared or approved Fusion's other products in development.
     Fusion is commercializing FloSeal and Proceed for controlling bleeding in
 a variety of settings in which conventional means of achieving hemostasis,
 such as sutures, staples, topical hemostats, or fibrin glues, are impractical
 or generally do not work effectively.  FloSeal, Proceed and Fusion's other
 products in development are based on a bio-resorbable and proprietary
 collagen-based gel.  Its products in development are being developed for use
 as hemostatic sealants, as well as for other potential uses.  Proceed is
 distributed worldwide exclusively by Sulzer Spine-Tech.
 
     Fusion Medical Technologies(TM), Fusion(TM), FloSeal(R), Proceed(TM), and
 the stylized Fusion logo are trademarks of Fusion.
 
     For further information, please contact: Lynn Johnson of Allen & Caron
 Inc, 949-474-4300, Lynn@allencaron.com, for Fusion Medical Technologies, Inc.
 
 SOURCE  Fusion Medical Technologies, Inc.